MonoparTherapeuticsInc..png
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
November 08, 2024 08:00 ET | Monopar Therapeutics Inc.
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid...
plus_logo.png
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
November 06, 2024 07:30 ET | Plus Therapeutics Inc.; Spectron RX
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
plus_logo.png
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
November 05, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
plus_logo.png
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
October 29, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
MonoparTherapeuticsInc..png
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
October 22, 2024 08:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer...
MonoparTherapeuticsInc..png
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
October 15, 2024 08:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
MonoparTherapeuticsInc..png
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
October 07, 2024 08:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
MNPR-101-Zr Total Body PET
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
September 12, 2024 08:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
plus_logo.png
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
2024.8.20 PR lu177 update Figure 1 jpeg
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
August 21, 2024 08:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...